News and Updates from the American Society of Clinical Oncology Annual Meeting
For the physicians treating men with non-metastatic castration resistant prostate cancer, knowing the risk of progression or death provides valuable information to guide the timing and selection of treatment.
Physicians and patients want to do everything possible to minimize the risk of breast cancer recurrence without incurring unnecessary toxicity from chemotherapy.
While guidelines for multiple myeloma advise pharmacologic prophylaxis to prevent development of venous thromboembolism (VTE) in high-risk patients, current risk assessment tools differ in the factors considered indicative of high risk and in the patients determined to need preventive anticoagulation.
Multiple organizations have recommended timely treatment for patients with lung cancer.
The treatment armamentarium for renal cell carcinoma and other genitourinary cancers continues to expand.
More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers.
BETHESDA, MD—Many reports have suggested that servicemembers who deployed to Iraq and Afghanistan developed respiratory illnesses at higher-than-expected rates, but study results looking at increased rates of asthma have been mixed. A new study by... View Article
WASHINGTON—In the past two years, the VA has implemented a nine-step process to minimize drug diversion, but cases continue to slip through. In December 2018, the VA’s Office of the Inspector General reported two instances... View Article
LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article
NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article
RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article
© 2000-2018. All Materials Copyright Marathon Medical Communications, Inc.